4 Theodorescu D, Wittke S, Ross M M, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol, 2006, 7: 230-240
[2]
5 Schaub S, Wilkins J, Weiler T, et al. Urine protein profiling with surface-enhanced laser-desorption//ionization time-of-flight mass spectrometry. Kidney Int, 2004, 65: 323-332
[3]
6 Jia L, Liu X, Liu L, et al. Urimem, a membrane that can store urinary proteins simply and economically, makes the large-scale storage of clinical samples possible. Sci China Life Sci, 2013, 57: 336-339
8 Thongboonkerd V, McLeish K R, Arthur J M, et al. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int, 2002, 62: 1461-1469
[6]
9 Garcia-Manzano A, Gonzalez-Llaven J, Lemini C, et al. Standardization of rat blood clotting tests with reagents used for humans. Proc West Pharmacol Soc, 2001, 44: 153-155
[7]
10 Wisniewski J R, Zougman A, Nagaraj N, et al. Universal sample preparation method for proteome analysis. Nat Methods, 2009, 6: 359-362
[8]
11 Keller A, Nesvizhskii A I, Kolker E, et al. Empirical statistical model to estimate the accuracy of peptide identifications made by ms/ms and database search. Anal Chem, 2002, 74: 5383-5392
[9]
1 Yi J, Kim C, Gelfand C A. Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma. J Proteome Res, 2007, 6: 1768-1781
[10]
2 Decramer S, Gonzalez de Peredo A, Breuil B, et al. Urine in clinical proteomics. Mol Cell Proteomics, 2008, 7: 1850-1862
[11]
3 Omenn G S, States D J, Adamski M, et al. Overview of the hupo plasma proteome project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics, 2005, 5: 3226-3245
[12]
12 Hauck S M, Dietter J, Kramer R L, et al. Deciphering membrane-associated molecular processes in target tissue of autoimmune uveitis by label-free quantitative mass spectrometry. Mol Cell Proteomics, 2010, 9: 2292-2305
[13]
13 Brunzel N. Fundamentals of Urine & Body Fluid Analysis. Philadelphia: Saunders, 2004. 480
[14]
14 Pieper R, Gatlin C L, Makusky A J, et al. The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics, 2003, 3: 1345-1364
[15]
15 Nagaraj N, Mann M. Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome. J Proteome Res, 2011, 10: 637-645
[16]
16 Adkins J N, Varnum S M, Auberry K J, et al. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics, 2002, 1: 947-955
[17]
17 Mehta A I, Ross S, Lowenthal M S, et al. Biomarker amplification by serum carrier protein binding. Dis Markers, 2003, 19: 1-10
[18]
18 Shen Y, Kim J, Strittmatter E F, et al. Characterization of the human blood plasma proteome. Proteomics, 2005, 5: 4034-4045
[19]
19 Kentsis A, Monigatti F, Dorff K, et al. Urine proteomics for profiling of human disease using high accuracy mass spectrometry. Proteomics Clin Appl, 2009, 3: 1052-1061
[20]
20 Wang L, Li F, Sun W, et al. Concanavalin A-captured glycoproteins in healthy human urine. Mol Cell Proteomics, 2006, 5: 560-562
[21]
21 Sleat D E, Zheng H, Lobel P. The human urine mannose 6-phosphate glycoproteome. Biochim Biophys Acta, 2007, 1774: 368-372
[22]
22 Yang N, Feng S, Shedden K, et al. Urinary glycoprotein biomarker discovery for bladder cancer detection using lc/ms-ms and label-free quantification. Clin Cancer Res, 2011, 17: 3349-3359
[23]
23 Halim A, Nilsson J, Rüetschi U, et al. Human urinary glycoproteomics; attachment site specific analysis of N- and O-linked glycosylations by CID and ECD. Mol Cell Proteomics, 2012, 11: M111.013649
[24]
24 Khadjavi A, Barbero G, Destefanis P, et al. Evidence of abnormal tyrosine phosphorylated proteins in the urine of patients with bladder cancer: the road toward a new diagnostic tool? J Urol, 2011, 185: 1922-1929
[25]
25 Liu L, Liu X, Sun W, et al. Unrestrictive identification of post-translational modifications in the urine proteome without enrichment. Proteome Sci, 2013, 11: 1
[26]
26 McDonald W H, Yates J R 3rd. Shotgun proteomics and biomarker discovery. Dis Markers, 2002, 18: 99-105
[27]
27 Chen T, Xie G, Wang X, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics, 2011, 10: M110 004945
[28]
28 Siwy J, Mullen W, Golovko I, et al. Human urinary peptide database for multiple disease biomarker discovery. Proteomics Clin Appl, 2011, 5: 367-374
[29]
29 Nicholson J K, Wilson I D. Understanding ‘global'' systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov, 2003, 2: 668-676
[30]
31 Wu T, Du Y, Han J, et al. Urinary angiostatin—a novel putative marker of renal pathology chronicity in lupus nephritis. Mol Cell Proteomics, 2013, 12: 1170-1179
[31]
32 Pories S E, Zurakowski D, Roy R, et al. Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev, 2008, 17: 1034-1042
[32]
33 Huang J T, Chaudhuri R, Albarbarawi O, et al. Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. Thorax, 2012, 67: 502-508
[33]
34 Thomas C E, Sexton W, Benson K, et al. Urine collection and processing for protein biomarker discovery and quantification. Cancer Epidemiol Biomarkers Prev, 2010, 19: 953-959
[34]
35 Weissinger E M, Wittke S, Kaiser T, et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int, 2004, 65: 2426-2434
[35]
36 Jantos-Siwy J, Schiffer E, Brand K, et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res, 2009, 8: 268-281
[36]
37 Lankisch P, Wessalowski R, Maisonneuve P, et al. Serum cystatin c is a suitable marker for routine monitoring of renal function in pediatric cancer patients, especially of very young age. Pediatr Blood Cancer, 2006, 46: 767-772
[37]
38 Lemm G, Kuppers J, Frey R, et al. Monitoring of proteinuria in phase i studies in healthy male subjects. Eur J Clin Pharmacol, 1998, 54: 287-294
[38]
30 Shao C, Li M, Li X, et al. A tool for biomarker discovery in the urinary proteome: a manually curated human and animal urine protein biomarker database. Mol Cell Proteomics, 2011, 10: M111 010975
